Title: Adenosine A<sub>2A</sub> Receptors and Neuroprotection
Abstract: Annals of the New York Academy of SciencesVolume 825, Issue 1 p. 30-48 Adenosine A2A Receptors and Neuroprotection ENNIO ONGINI, Corresponding Author ENNIO ONGINI Schering-Plough Research Institute San Raffaele Science Park Via Olgettina, 58 I-20132 Milan, Italy Corresponding author. Tel: +39 2 21219.201; fax: +39 2 21219.253; email: [email protected]Search for more papers by this authorMARINA ADAMI, MARINA ADAMI Schering-Plough Research Institute San Raffaele Science Park Via Olgettina, 58 I-20132 Milan, ItalySearch for more papers by this authorCINZIA FERRI, CINZIA FERRI Schering-Plough Research Institute San Raffaele Science Park Via Olgettina, 58 I-20132 Milan, ItalySearch for more papers by this authorROSALIA BERTORELLI, ROSALIA BERTORELLI Schering-Plough Research Institute San Raffaele Science Park Via Olgettina, 58 I-20132 Milan, ItalySearch for more papers by this author ENNIO ONGINI, Corresponding Author ENNIO ONGINI Schering-Plough Research Institute San Raffaele Science Park Via Olgettina, 58 I-20132 Milan, Italy Corresponding author. Tel: +39 2 21219.201; fax: +39 2 21219.253; email: [email protected]Search for more papers by this authorMARINA ADAMI, MARINA ADAMI Schering-Plough Research Institute San Raffaele Science Park Via Olgettina, 58 I-20132 Milan, ItalySearch for more papers by this authorCINZIA FERRI, CINZIA FERRI Schering-Plough Research Institute San Raffaele Science Park Via Olgettina, 58 I-20132 Milan, ItalySearch for more papers by this authorROSALIA BERTORELLI, ROSALIA BERTORELLI Schering-Plough Research Institute San Raffaele Science Park Via Olgettina, 58 I-20132 Milan, ItalySearch for more papers by this author First published: 17 December 2006 https://doi.org/10.1111/j.1749-6632.1997.tb48412.xCitations: 85Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat REFERENCES 1 Rudolphi, K. A., P. Schubert, F. E. Parkinson & B. B. Fredholm. 1992. Neuroprotective role of adenosine in cerebral ischemia. Trends Pharmacol. Sci. 13: 439–445. 10.1016/0165-6147(92)90141-R CASPubMedWeb of Science®Google Scholar 2 Matsumoto, K., R. Graf, G. Rosner, N. Shimada & W. D. Heiss. 1992. Flow thresholds for extracellular purine catabolite elevation in cat focal ischemia. Brain Res. 579: 309–314. 10.1016/0006-8993(92)90066-I CASPubMedWeb of Science®Google Scholar 3 Rubio, R., V. T. Widmeier & R. M. Berne. 1974. Relationship between coronary flow and adenosine production and release. J. Mol. Cell Cardiol. 6: 651–656. 10.1016/0022-2828(74)90036-4 Web of Science®Google Scholar 4 During, M. J. & D. D. Spencer. 1992. Adenosine: a potential mediator of seizures arrest and postictal refractoriness. Ann Neurol. 32: 618–624. 10.1002/ana.410320504 CASPubMedWeb of Science®Google Scholar 5 Young, D. & M. Dragunow. 1994. Status epilepticus may be caused by loss of adenosine anticonvulsant mechanisms. Neuroscience 58: 245–261. 10.1016/0306-4522(94)90032-9 CASPubMedWeb of Science®Google Scholar 6 Ongini, E. & B. B. Fredholm. 1996. Pharmacology of adenosine A2A receptors. Trends Pharmacol. Sci. 17: 364–372. 10.1016/S0165-6147(96)80010-1 CASPubMedWeb of Science®Google Scholar 7 Stone, T. W., M. G. Collins, M. Williams, L. P. Miller, A. Karasawa & D. Hillaire-Buys. 1995. Adenosine: some therapeutic applications and prospects. In Pharmacological Sciences Perspectives for Research and Therapy in the Late 1990s. A. C. Cuello & B. Coller, Eds. 303–309. Birkhäuser Verlag. Basel . 10.1007/978-3-0348-7218-8_30 Web of Science®Google Scholar 8 Jarvis, M. F., & M. Williams. 1989. Adenosine in central nervous system function. In Adenosine and Adenosine Receptors. M. Williams, Ed. 432–474. Humana Press. Clifton . Google Scholar 9 Parkinson, F. E. & B. B. Fredholm. 1990 Autoradiographic evidence for G-protein coupled A2 receptors in rat neostriatum using [3H]CGS 21680 as a ligand Naunyn-Schmiedebergs. Arch. Pharmacol. 342: 85–89. 10.1007/BF00178977 CASPubMedWeb of Science®Google Scholar 10 Schiffmann, S. N., O. Jacobs & J. J. Vanderhaeghen. 1991. Striatal restricted adenosine A2 receptor (RCD8) is expressed by enkephalin but not by substance P neurons: an in situ hybridization histochemistry study. J. Neurochem. 57: 1062–1067. 10.1111/j.1471-4159.1991.tb08257.x CASPubMedWeb of Science®Google Scholar 11 Kurokawa, M., I. P. Kirk, K. A. Kirkpatrick, H. Kase & P. J. Richardson. 1994. Inhibition by KF17837 of adenosine A2A receptor mediated modulation of striatal GABA and ACh release. Br. J. Pharmacol. 113: 43–48. 10.1111/j.1476-5381.1994.tb16171.x CASPubMedWeb of Science®Google Scholar 12 Sebastiao, A. M. & J. A. Ribeiro. 1992. Evidence for the presence of excitatory A2 adenosine receptors in the rat hippocampus. Neurosci. Lett. 138: 41–44. 10.1016/0304-3940(92)90467-L CASPubMedWeb of Science®Google Scholar 13 Cunha, R. A., B. Johansson, I. Van Der Ploeg, A. M. Sebastio, J. A. Ribeiro & B. B. Fredholm. 1994. Evidence for functionally important adenosine A2A receptors in the rat hippocampus. Brain Res. 649: 208–216. 10.1016/0006-8993(94)91066-9 CASPubMedWeb of Science®Google Scholar 14 Barraco, R. A., A. Martens, M. Parizon & H. J. Normile. 1993. Adenosine A2A receptors in the nucleus accumbens mediate locomotor depression. Brain Res. Bull. 31: 397–404. 10.1016/0361-9230(93)90233-2 CASPubMedWeb of Science®Google Scholar 15 Kirk, I. P. & P. Richardson. 1995. Further characterisation of [3H]CGS 21680 binding sites in the rat striatum and cortex. Br. J. Pharmacol. 114: 537–548. 10.1111/j.1476-5381.1995.tb13260.x CASPubMedWeb of Science®Google Scholar 16 Dixon, A. K., A. K. Gubitz, D. J. Sirinathsinghji, P. J. Richardson & T. C. Freeman. 1996. Tissue distribution of adenosine receptor mRNAs in the rat. Br. J. Pharmacol. 118: 1461–1468. 10.1111/j.1476-5381.1996.tb15561.x CASPubMedWeb of Science®Google Scholar 17 Parkinson, F. E., B. Johansson, K. Lindström & B. B. Fredholm. 1996. Adenosine A1 and A2A receptors and nitrobenzylthioinosine-sensitive transporters in gerbil brain: no changes following long-term treatment with the adenosine transport inhibitor propentophylline. Neuropharmacology 35: 79–89. 10.1016/0028-3908(95)00155-7 CASPubMedWeb of Science®Google Scholar 18 Fink, J. S., D. R. Weaver, S. A. Rivkees, R. Peterfreund, R. Pollak, E. Adler & S. M. Reppert. 1992. Molecular cloning of a rat A2 adenosine receptor: selective co-expression with D2 dopamine receptors in rat striatum. Mol. Brain Res. 14: 186–195. 10.1016/0169-328X(92)90173-9 CASPubMedWeb of Science®Google Scholar 19 Martinez-Mir, M. I., A. Probst & J. M. Palacios. 1991. Adenosine A2 receptors: selective localization in the human basal ganglia and alterations with disease. Neuroscience 42: 697–706. 10.1016/0306-4522(91)90038-P CASPubMedWeb of Science®Google Scholar 20 Casati, C., A. Monopoli, A. Forlani, E. Bonizzoni & E. Ongini. 1994. Telemetry monitoring of hemodynamic effects induced over time by adenosine agonists in spontaneously hypertensive rats. J. Pharmacol. Exp. Ther. 275: 914–919. PubMedWeb of Science®Google Scholar 21 Dionisotti, S., S. Ferrara, C. Molta, C. Zocchi & E. Ongini. 1996. Labelling of the A2A adenosine receptors in human platelets using the non-xanthine antagonist radioligand [3H]SCH 58261. J. Pharmacol. Exp. Ther. 278: 1209–1214. CASPubMedWeb of Science®Google Scholar 22 Fredholm, B. B., Y. Zhang & I. Van Der Ploeg. 1996. Adenosine A2A receptors mediate the inhibitory effect of adenosine on formyl-Met-Leu-Phe-stimulated respiratory burst in neutrophil leukocytes. Naunyn-Schmiedebergs Arch. Pharmacol. 354: 262–267. 10.1007/BF00171056 CASPubMedWeb of Science®Google Scholar 23 Jacobson, K. A., P. J. M. Van Galen & M. Williams. 1992. Adenosine receptors: pharmacology, structure-activity relationship and therapeutic potential. J. Med. Chem. 35: 407–422. 10.1021/jm00081a001 CASPubMedWeb of Science®Google Scholar 24 Cristalli, G., R. Volpini, S. Vittori, E. Camaioni, A. Monopoli, A. Conti, S. Dionisotti, C. Zocchi & E. Ongini. 1994. 2-Alkynyl derivates of adenosine-5′-N-ethyl-uronamide (NECA): selective A2 adenosine receptor agonists with potent inhibitory activity on platelet aggregation. J. Med. Chem. 37: 1720–1726. 10.1021/jm00037a024 CASPubMedWeb of Science®Google Scholar 25 Cristalli, G., E. Camaioni, S. Vittori, R. Volpini, P. A. Borea, A. Conti, S. Dionisotti, E. Ongini & A. Monopoli. 1995. 2-Aralkynyl and 2-heteroalkynyl derivates of adenosine-5′-N-ethyluronamide as selective A2A adenosine receptor agonists. J. Med. Chem. 38: 1462–1672. 10.1021/jm00009a007 CASPubMedWeb of Science®Google Scholar 26 Vittori, S., E. Camaioni, E. Di Francesco, R. Volpini, A. Monopoli, S. Dionisotti, E. Ongini & G. Cristalli. 1996. 2-Alkenyl and 2-alkyl derivatives of adenosine and adenosine-5′-ethyluronamide: different affinity and selectivity of E- and Z-diastereomers at A2A adenosine receptors. J. Med. Chem. 39: 4211–4217. 10.1021/jm960376g CASPubMedWeb of Science®Google Scholar 27 Adami, M., B. Bertorelli, N. Ferri, M. C. Foddi & E. Ongini. 1995. Effects of repeated administration of selective adenosine A1 and A2A receptor agonists on pentylenetetrazole-induced convulsions in the rat. Eur. J. Pharmacol. 294: 383–389. 10.1016/0014-2999(95)00557-9 CASPubMedWeb of Science®Google Scholar 28 Casati, C., A. Monopoli, S. Dionisotti, C. Zocchi, E. Bonizzoni & E. Ongini. 1994. Repeated administration of selective adenosine A1 and A2 receptor agonists in the spontaneously hypertensive rat: tolerance develops to A1-mediated hemodynamic effects. J. Pharmacol. Exp. Ther. 268: 1506–1551. CASPubMedWeb of Science®Google Scholar 29 Shimada, J., F. Suzuki, H. Nokada, A. Ishii & S. Ichikawa. 1992. (E)-1,3-Dialkyl-7-methyl-8-(3,4,5-trimethoxystyryl)xanthines: potent and selective adenosine A2 antagonists. J. Med. Chem. 36: 2342–2345. 10.1021/jm00090a027 CASWeb of Science®Google Scholar 30 Nonaka, Y., J. Shimada, H. Nonaka, N. Koike, N. Aoki, H. Kobayashi, H. Kase, K. Yamaguchi & F. Suzuki. 1993. Photoisomerization of a potent and selective adenosine A2 antagonist, (E)-1,3-dipropyl-8-(3,4-dimethoxystyryl)-7-methylxanthine. J. Med. Chem. 36: 3731–3733. 10.1021/jm00075a031 CASPubMedWeb of Science®Google Scholar 31 Jacobson, K. A., B. Gallo-Rodriquez, N. Melman, B. Fisher, M. Maillard, A. Van Bergen, P. J. M. Van Galen & Y. Karton. 1993. Structure-activity relationships of 8-styrylxanthines as A2 selective adenosine antagonists. J. Med. Chem. 36: 1333–1342. 10.1021/jm00062a005 CASPubMedWeb of Science®Google Scholar 32 Williams, M., J. Francis, G. Ghai, A. Braunwalder, S. Psychoyos, G. A. Stone & W. D. Cash. 1987. Biochemical characterization of the triazoloquinazoline, CGS 15943, a novel, nonxanthine adenosine antagonist. J. Pharmacol. Exp. Ther. 241: 415–420. CASPubMedWeb of Science®Google Scholar 33 Baraldi, P. G., S. Manfredini, D. Simoni, L. Zappaterra, C. Zocchi, S. Dionisotti & E. Ongini. 1994. Synthesis of new pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine and 1,2,3-triazolo[1,5-c]pyrimidine displaying potent and selective activity as A2A adenosine receptor antagonists. Bioorg. Med. Chem. Lett. 4: 2539–2544. 10.1016/S0960-894X(01)80279-1 CASWeb of Science®Google Scholar 34 Baraldi, P. G., B. Cacciari, G. Spalluto, S. Dionisotti, M. J. Pineda De Las Infantas Y Villatoro, C. Zocchi & E. Ongini. 1996. Pyrazolo(4,3-e)1,2,4-triazolo(1,5-c)pyrimidine derivatives: potent and selective A2A adenosine antagonists. J. Med. Chem. 39: 1164–1171. 10.1021/jm950746l CASPubMedWeb of Science®Google Scholar 35 Zocchi, C., E. Ongini, A. Conti, A. Monopoli, A. Negretti, P. G. Baraldi & S. Dionisotti. 1996. The non-xanthine heterocyclic compound SCH 58261 is a new potent and selective A2A adenosine receptor antagonist. J. Pharmacol. Exp. Ther. 276: 398–404. CASPubMedWeb of Science®Google Scholar 36 Zocchi, C., E. Ongini, S. Ferrara, P. G. Baraldi & S. Dionisotti. 1996. Binding of the radioligand [3H]SCH 58261, a new non-xanthine A2A adenosine receptor antagonist, to rat striatal membranes. Br. J. Pharmacol. 117: 1381–1386. 10.1111/j.1476-5381.1996.tb15296.x CASPubMedWeb of Science®Google Scholar 37 Belardinelli, L., J. C. Shryock, J. Ruble, A. Monopoli, S. Dionisotti, E. Ongini, D. M. Dennis & S. P. Baker. 1996. Binding of the novel non-xanthine A2A adenosine receptor antagonist [3H]SCH 58261 to coronary artery membranes. Circ. Res. 79: 1153–1160. 10.1161/01.RES.79.6.1153 CASPubMedWeb of Science®Google Scholar 38 Dionisotti, S., E. Ongini, C. Zocchi, B. Kull, G. Arslan & B. B. Fredholm. 1997. Characterization of human A2A adenosine receptors using the antagonist radioligand [3H]SCH 58261. Br. J. Pharmacol. In press. 10.1038/sj.bjp.0701119 PubMedWeb of Science®Google Scholar 39 Bertorelli, R., N. Ferri, M. Adami & E. Ongini. 1996. Effects of selective agonists and antagonists for A1 or A2A adenosine receptors on sleep-walking patterns in rats. Drug Dev. Res. 37: 65–72. 10.1002/(SICI)1098-2299(199602)37:2<65::AID-DDR1>3.0.CO;2-J CASWeb of Science®Google Scholar 40 Poucher, S. M., J. R. Keddie, P. Singh, S. M. Stoggall, P. W. R. Caulkett, G. Jones & M. G. Collis. 1995. The in vitro pharmacology of ZM 241385, a potent, non-xanthine, A2A selective adenosine antagonist. Br. J. Pharmacol. 115: 1096–1102. 10.1111/j.1476-5381.1995.tb15923.x CASPubMedWeb of Science®Google Scholar 41 Dragunow, M., G. V. Goddard & R. Laverty. 1985. Is adenosine an endogenous anticonvulsant Epilepsia 26: 480–487. 10.1111/j.1528-1157.1985.tb05684.x CASPubMedWeb of Science®Google Scholar 42 Zhang, G., P. H. Franklin & T. F. Murray. 1993. Manipulation of endogenous adenosine in the rat prepiriform cortex modulates seizures susceptibility. J. Pharmacol. Exp. Ther. 264: 1415–1424. CASPubMedWeb of Science®Google Scholar 43 Von Lubitz, D. K. J. E., M. F. Carter & K. A. Jacobson. 1993. Effects of N6-cyclopentyl-adenosine and 8-cyclopentyl-1,3-dipropylxanthine on N-methyl-D-aspartate induced seizures in mice. Eur. J. Pharmacol. 249: 265–270. 10.1016/0014-2999(93)90521-I CASPubMedWeb of Science®Google Scholar 44 Von Lubitz, D. K. J. E., M. F. Carter, S. I. Deutsch, R. C. S. Lin, J. Mastropaolo, Y. Meshulan & K. A. Jacobson. 1995. The effects of adenosine A3 receptor stimulation on seizures in mice. Eur. J. Pharmacol. 275: 23–29. 10.1016/0014-2999(94)00734-O PubMedWeb of Science®Google Scholar 45 Klitgaard, H., L. J. S. Knutsen & C. Thomsen. 1993. Contrasting effects of adenosine A1 and A2 receptor ligands in different chemoconvulsive rodent models. Eur. Pharmacol. 242: 221–228. 10.1016/0014-2999(93)90245-D CASPubMedWeb of Science®Google Scholar 46 Von Lubitz, D. K. J. E., M. F. Carter, M. Beenhakker, R. C. S. Lin & K. A. Jacobsen. 1995. Adenosine: a prototherapeutic concept in neurodegeneration. Ann. N. Y. Acad. Sci. 765: 163–178. 10.1111/j.1749-6632.1995.tb16573.x PubMedWeb of Science®Google Scholar 47 Dunwiddie, T. V. & T. Worth. 1982. Sedative and anticonvulsant effects of adenosine analogs in mouse and rat. J. Pharmacol. Exp. Ther. 220: 70–76. CASPubMedWeb of Science®Google Scholar 48 Monopoli, A., A. Conti, S. Dionisotti, C. Casati, E. Camaioni, G. Cristalli & E. Ongini. 1994. Pharmacology of the highly selective A1 adenosine receptor agonist 2-chloro-N6-cyclopentyladenosine. Arzneim.-Forsch./Drug Res. 44: 1305–1312. CASPubMedWeb of Science®Google Scholar 49 Monopoli, A., A. Conti, C. Zocchi, C. Casati, E. Camaioni, R. Volpini, G. Cristalli & E. Ongini. 1994. Pharmacology of the new selective A2A adenosine receptor agonist 2-hexynyl-5′-N-ethylcarboxamidoadenosine. Arzneim.-Forsch./Drug Res. 44: 1296–1304. CASPubMedWeb of Science®Google Scholar 50 Ongini, E., S. Dionisotti, M. Morelli, S. Ferré, P. Svenningsson, K. Fuxe & B. B. Fredholm. 1996. Neuropharmacology of the adenosine A2A receptors. Drug. Dev. Res. 39: 450–460. 10.1002/(SICI)1098-2299(199611/12)39:3/4<450::AID-DDR27>3.0.CO;2-3 CASWeb of Science®Google Scholar 51 Fuxe, K., S. Ferré, P. Snaprud, G. Von Euler, B. Johansson & B. B. Fredholm. 1993. Antagonistic A2A/D2 receptor interactions in the striatum as a basis for adenosine/dopamine interactions in the central nervous system. Drug. Dev. Res. 28: 374–380. 10.1002/ddr.430280334 CASWeb of Science®Google Scholar 52 Ferré, S., K. Fuxe, G. Von Euler, R. Johansson & B. B. Fredholm. 1992. Adenosinedopamine interactions in the brain. Neuroscience 51: 501–512. 10.1016/0306-4522(92)90291-9 CASPubMedWeb of Science®Google Scholar 53 Kanda, T., S. Shiozaki, J. Shimada, F. Suzuki, & J. Nakamura. 1994. KF 17837: a novel selective adenosine A2A receptor antagonist with anticataleptic activity. Eur. J. Pharmacol. 256: 263–268. 10.1016/0014-2999(94)90551-7 CASPubMedWeb of Science®Google Scholar 54 Fenu, S., A. Pinna, E. Ongini & M. Morelli. 1997. Blockade of adenosine A2A receptors potentiates L-DOPA-induced turning behaviour and c-fos expression in unilaterally 6-hydroxydopamine lesioned rats. Eur. J. Pharmacol. 321: 143–147. 10.1016/S0014-2999(96)00944-2 CASPubMedWeb of Science®Google Scholar 55 Morelli, M., A. Pinna, S. Fenu & G. Di Chiara. 1994. Adenosine A2 receptors interact negatively with dopamine D1 and D2 receptors in unilaterally 6-hydroxydopamine-lesioned rats. Eur. J. Pharmacol. 251: 21–25. 10.1016/0014-2999(94)90438-3 CASPubMedWeb of Science®Google Scholar 56 Pinna, A., G. Di Chiara, J. Wardas & M. Morelli. 1996. Blockade of A2A adenosine receptors positively modulates turning behaviour and c-Fos expression induced by D1 agonists in dopamine-denervated rats. Eur. J. Neurosci. 8: 1176–1181. 10.1111/j.1460-9568.1996.tb01285.x CASPubMedWeb of Science®Google Scholar 57 Le Moine, C., E. Normand & B. Bloch. 1991. Phenotypical characterization of the rat striatal neuron expressing the D1 dopamine receptor gene. Proc. Natl. Acad. Sci. USA 88: 4205–4209. 10.1073/pnas.88.10.4205 PubMedWeb of Science®Google Scholar 58 Dragunow, M. & R. L. M. Faull. 1988. Neuroprotective effects of adenosine. Trends Pharmacol. Sci. 9: 193–194. 10.1016/0165-6147(88)90079-X PubMedWeb of Science®Google Scholar 59 Fredholm, B. B., B. Johansson, I. Van Der Ploeg, P. S. Hu & S. Jin. 1993. Neuromodulatory roles of purines. Drug. Dev. Rev. 28: 349–353. 10.1002/ddr.430280329 CASWeb of Science®Google Scholar 60 Choi, D. W. 1992. Excitotoxic cell death. J. Neurobiol. 23: 1261–1276. 10.1002/neu.480230915 CASPubMedGoogle Scholar 61 Koroshetz, W. J. & M. A. Moskowitz. 1996. Emerging treatments for stroke in humans. Trends Pharmacol. Sci. 17: 227–229. 10.1016/0165-6147(96)10020-1 CASPubMedWeb of Science®Google Scholar 62 Heron, A., F. Lasbennes & J. Seylaz. 1993. Adenosine modulation of amino acid release in rat hippocampus during ischemia and veratridine depolarization. Brain Res. 608: 27–32. 10.1016/0006-8993(93)90769-J CASPubMedWeb of Science®Google Scholar 63 O'regan, M. H., R. E. Simpson, L. M. Perkins & J. W. Phillis. 1992. The selective A2 adenosine receptor agonist CGS 21680 enhances excitatory transmitter amino acid release from the ischemic rat cerebral cortex. Neurosci. Lett. 138: 169–172. 10.1016/0304-3940(92)90498-V CASPubMedWeb of Science®Google Scholar 64 Andine, P., K. A. Rudolphi, B. B. Fredholm & H. Hagberg. 1990. Effect of propentophylline (HWA 285) on extracellular purines and excitatory amino acids in CA1 of rat hippocampus during transient ischemia. Br. J. Pharmacol. 100: 814–818. 10.1111/j.1476-5381.1990.tb14097.x CASPubMedWeb of Science®Google Scholar 65 Corradetti, R., G. Lo Conte, F. Passani & G. Pepeu. 1984. Adenosine decreases aspartate and glutamate release from rat hippocampal slices. Eur. J. Pharmacol. 104: 19–26. 10.1016/0014-2999(84)90364-9 CASPubMedWeb of Science®Google Scholar 66 Dolphin, A. C. & E. R. Archer. 1983. An adenosine agonist inhibits and a cyclic AMP analogue enhances the release of glutamate but not GABA from slices of rat dentate gyrus. Neurosci. Lett. 43: 49–54. 10.1016/0304-3940(83)90127-1 CASPubMedGoogle Scholar 67 Fredholm, B. B. & T. V. Dunwiddie. 1988. How does adenosine inhibit transmitter release Trends Pharmacol. Sci. 9: 130–134. 10.1016/0165-6147(88)90194-0 CASPubMedWeb of Science®Google Scholar 68 Cronstein, B. N. 1994. Adenosine, an endogenous anti-inflammatory agent. J. Appl. Physiol. 76: 5–9. 10.1152/jappl.1994.76.1.5 CASPubMedWeb of Science®Google Scholar 69 Von Lubitz, D. K. J. E., J. M. Dambrosia & D. J. Redmond. 1989. Protective effect of cyclohexyl adenosine in treatment of cerebral ischemia in gerbils. Neuroscience 2: 451–457. 10.1016/0306-4522(89)90265-0 Web of Science®Google Scholar 70 Phillis, J. W. 1995. The effects of selective A1 and A2 adenosine receptor antagonists on cerebral ischemic injury in the gerbil. Brain Res. 705: 79–84. 10.1016/0006-8993(95)01153-6 CASPubMedWeb of Science®Google Scholar 71 Kogure, K., P. Scheinberg, R. Busto & O. M. Reinmuth. 1975. An effect of aminophylline in experimental cerebral ischemia. Arch. Neurol. 32: 352. Web of Science®Google Scholar 72 Seida, M., H. G. Wagner, K. Vass & I. Klatzo. 1988. Effect of aminophylline on postischemic edema and brain damage in cats. Stroke 19: 1275–1282. 10.1161/01.STR.19.10.1275 CASPubMedWeb of Science®Google Scholar 73 Morii, S., A. C. Ngai, K. R. Ko & H. R. Winn. 1987. Role of adenosine in regulation of cerebral blood flow: effects of theophylline during normoxia and hypoxia. Am. J. Physiol. 253: H165–H175. CASPubMedWeb of Science®Google Scholar 74 Rudolphi, K. A., M. Keil, J. Fastbom, J. J. Grome & B. B. Fredholm. 1990. Contrary effects of acute versus chronic caffeine administration on ischemically induced hippocampal damage in the gerbil-involvement of adenosine receptors? In Targets for New Drugs. Purines in Cellular Signaling. K. A. Jacobson, J. W. Daly & V. Manganiello, Eds. 411–412. Springer. New York . Google Scholar 75 Sutherland, G. R., J. Peeling, H. J. Lesiuk, R. M. Brownstone, M. Rydzy, J. K. Saunders & J. D. Geiger. 1991. The effects of caffeine on ischemic neuronal injury as determined by magnetic resonance imaging and histopathology. Neuroscience 42: 171–182. 10.1016/0306-4522(91)90157-J CASPubMedWeb of Science®Google Scholar 76 Rudolphi, K. A., M. Keil, J. Fastbom & B. B. Fredholm. 1989. Ischaemic damage in gerbil hippocampus is reduced following upregulation of adenosine (A1) receptors by caffeine treatment. Neurosci. Lett. 103: 275–280. 10.1016/0304-3940(89)90112-2 CASPubMedWeb of Science®Google Scholar 77 Simpson, R. E., M. H. O'regan, L. M. Perkins & J. W. Phillis. 1992. Excitatory transmitter amino acid release from ischemic rat cerebral cortex: effects of adenosine receptor agonists and antagonists. J. Neurochem. 58: 1683–1690. 10.1111/j.1471-4159.1992.tb10041.x CASPubMedWeb of Science®Google Scholar 78 Cunha, R. A., E. Milusheva, E. S. Vizi, J. A. Ribeiro & A. M. Sebastio. 1994. Excitatory and inhibitory effects of A1 and A2A adenosine receptor activation on the electrically evoked [3H]acetylcholine release from different areas of the rat hippocampus. J. Neurochem. 63: 207–214. 10.1046/j.1471-4159.1994.63010207.x CASPubMedWeb of Science®Google Scholar 79 Castillo-Melendez, M., E. Krstew, A. J. Lawrence & B. Jarrott. 1994. Presynaptic adenosine A2A receptors on soma and central terminals of rat vagal afferent neurons. Brain Res. 652: 137–144. 10.1016/0006-8993(94)90327-1 CASPubMedWeb of Science®Google Scholar 80 Cunha, R. A., P. C. De Saà, A. M. Sebastiao & J. A. Ribeiro. 1996. Preferential activation of excitatory adenosine receptors at rat hippocampal and neuromuscular synapses by adenosine formed from released adenine nucleotides. Br. J. Pharmacol. 119: 253–260. 10.1111/j.1476-5381.1996.tb15979.x CASPubMedWeb of Science®Google Scholar 81 Gao, Y. & J. W. Phillis. 1994. CGS 15943, an adenosine A2 receptor antagonist, reduces cerebral ischemic injury in the Mongolian gerbil. Life Sci. 55: 61–65. 10.1016/0024-3205(94)00889-2 CASWeb of Science®Google Scholar 82 Von Lubitz, D. K. J. E., R. C. S. Lin & K. A. Jacobson. 1995 Cerebral ischemia in gerbils: effects of acute and chronic treatment with adenosine A2A receptor agonist and antagonist. Eur. J. Pharmacol. 287: 295–302. 10.1016/0014-2999(95)00498-X PubMedWeb of Science®Google Scholar 83 Jacobson, K. A., D. K. J. E. Von Lubitz, J. W. Daly & B. B. Fredholm. 1996. Adenosine receptor ligands: differences with acute versus chronic treatment. Trends Pharmacol. Sci. 17: 108–113. 10.1016/0165-6147(96)10002-X CASPubMedWeb of Science®Google Scholar 84 Von Lubitz, D. K. J. E., R. C. S. Lin, N. Nelman, X. Ji, M. F. Carter & K. A. Jacobson. 1994. Chronic administration of selective adenosine A1 receptor agonist or antagonist in cerebral ischemia. Eur. J. Pharmacol. 256: 161–167. 10.1016/0014-2999(94)90241-0 CASPubMedWeb of Science®Google Scholar 85 Lupica, C. R., R. F. Berman & M. F. Jarvis. 1991. Chronic theophylline treatment increases adenosine A1 but not adenosine A2 binding in the rat brain-an autoradiographic study. Synapse 9: 95–99. 10.1002/syn.890090203 CASPubMedWeb of Science®Google Scholar 86 Abbracchio, M. P., G. Fogliatto, A. M. Paoletti, G. E. Rovati & F. Cattabeni. 1992. Prolonged in vitro exposure of rat brain slices to adenosine analogues: selective desensitization of adenosine A1 but not A2 receptors. Eur. J. Pharmacol. Mol. Pharmacol. Sect. 227: 317–324. 10.1016/0922-4106(92)90010-S CASPubMedWeb of Science®Google Scholar Citing Literature Volume825, Issue1Neuroprotective Agents: Third International ConferenceOctober 1997Pages 30-48 ReferencesRelatedInformation
Publication Year: 1997
Publication Date: 1997-10-01
Language: en
Type: review
Indexed In: ['crossref', 'pubmed']
Access and Citation
Cited By Count: 103
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot